# TXINNO Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/txinno-bioscience

- Industry: Pharmaceuticals
- Headquarters: Yongin, South Korea
- Website: www.txinno.com
- Total disclosed funding: $14M
- Latest round: Series B (Dec 15, 2022)
- Investors on record: 7

## About

Founded in 2020 and based in Yongin, South Korea, TXINNO Bioscience operates as a researcher and manufacturer of molecular immuno-oncology drugs. The company utilizes artificial intelligence technology to develop certain enzyme-inhibiting drugs and therapeutics that allow the activation of innate immunity in cancer patients. In March 2023,TXINNO Bioscience raised KRW 2 billion in venture funding from new investors Korea Venture Investment Corporation and Hyundai Pharm. As of 2023, the company is led by its CEO Park Chan-sun.

The company will use the March funding to accelerate phase 1 clinical research of its core pipeline, ENPP1 inhibitor 'TXN10128'.

## Funding rounds

- Series B, Dec 15, 2022, $7.7M — Korea Investment Partners, Solidus Investment, Company K Partners, DAYLI Partners, Medytox Venture Investment
- Series A, Aug 20, 2021, $5.9M — Korea Investment Partners, DSC Investment, Company K Partners, Schmidt
- Seed, Sep 23, 2020 — Schmidt

## Investors

- Schmidt (https://capitalatlas.ai/funds/schmidt) — Seed, Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A, Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A, Series B
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series B